GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Pre-Tax Income

Royalty Pharma (Royalty Pharma) Pre-Tax Income

: $1,700 Mil (TTM As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Royalty Pharma's pretax income for the three months ended in Dec. 2023 was $718 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $1,700 Mil. Royalty Pharma's pretax margin was 120.39%.

During the past 7 years, Royalty Pharma's highest Pretax Margin was 135.67%. The lowest was 10.28%. And the median was 80.19%.


Royalty Pharma Pre-Tax Income Historical Data

The historical data trend for Royalty Pharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Premium Member Only Premium Member Only 2,461.42 1,701.95 1,241.20 230.06 1,700.09

Royalty Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -610.03 509.09 351.34 122.08 717.59

Competitive Comparison

For the Biotechnology subindustry, Royalty Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Pre-Tax Income falls into.



Royalty Pharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Royalty Pharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=1492.15+322.834+-187.187+72.291+-2.2737367544323E-13
=1,700

Royalty Pharma's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=612.896+145.445+-47.255+6.5+0
=718

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,700 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma  (NAS:RPRX) Pre-Tax Income Explanation

Royalty Pharma's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=717.586/596.068
=120.39%

During the past 7 years, Royalty Pharma's highest Pretax Margin was 135.67%. The lowest was 10.28%. And the median was 80.19%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma (Royalty Pharma) Business Description

Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Executives
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne officer: EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta director, officer: CEO, Chairman of the Board 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd officer: EVP, Investments & GC C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani director, 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic 10 percent owner C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a. 10 percent owner 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert director 110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez director MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080